Table 3.

Recently reported nanosuspension based parenteral formulations.

Nos.	Active ingredient	Category	Method of nanosuspension production	Surfactant used	Concentration of surfactant used	Purpose of the study	Refs.
1	p-Terphynyl derivative	Anticancer	Precipitation-microfluidization method	Pluronic F-68	0.08%, w/v	Solubility enhancement	16
2	Etoposide	Anticancer	High pressure homogenization –solvent precipitation	Bovin serum albumin	3%, w/v	Targeted delivery	96
3	Azithromycin	Antibiotic	Reactive precipitation method	Soybean Lecithin	1%	Targeted delivery	97
4	Fenofibrate	Reduces cholesterol level	Stirred ball mill	HPMC	5%, 7.5%, 10%	Controlled delivery	98
5	Silybin	Hepatoprotective	High pressure homogenization	Lecithin Poloxamer 188	0.2% and 0.1%, respectively	Solubility enhancement	99
6	Simvastatin	Lipid lowering agent	Nanoprecipitation technique	PVP K-30SLS	4% and 0.02%, respectively	Solubility enhancement	100
7	Itraconazole	Anti-fungal	_	Poloxamer 188	–	Solubility enhancement	19
8	Clofazimine	Antimycobacterial	High pressure homogenizer	Pluronic F-68	0.5%	Targeted delivery, Stability	101
9	Paclitaxel	Anticancer	High-pressure homogenizer	Human serum albumin PEG	4.5% and 10%. respectively	Targeted delivery	102
10	Hyaluronic acid and paclitaxel	Anticancer	Electrostatic attraction method	Pluronic F-127 Chitosan	–	Targeted delivery	103
11	Paclitaxel	Anticancer	Antisolvent precipitation method (probe sonication)	PVP K-30	0.01%	Targeted delivery	68
12	Bexarotene	Anticancer	High pressure homogenizer	Pluronic F-68	0.02%	Solubility enhancement	104
13	Paclitaxel	Anticancer	High pressure homogenizer	Sodium poly styrene sulphonate	0.1%, 0.1%, 0.5% and 0.5%, respectively	Solubility enhancement	105
				Glycon Chitosan
				Tween 80
14	Bexarotene	Anticancer	Precipitation + microfluidization	Pluronic F-68	0.5%	Targeted delivery	106
15	Paclitaxel 1-methyltryptophan	Anticancer	Nano-precipitation method	PVA	2% of both	Targeted delivery	107
				Pluronic F-68
16	Paclitaxel	Anticancer	Wet media milling method	Cremophor EL	0.1%	Targeted delivery	108
17	Paclitaxel	Anticancer	Nano-precipitation method	TPGS	0.4%	Toxicity and PK study	109
18	Paclitaxel	Anticancer	Nano-precipitation method	TPGS	0.4%	Drug resistance study	110
19	Paclitaxel	Anticancer	High pressure homogenization	Poloxamer 188	0.08%	PK evaluation study	64
				PEG-400
				Tween-80
				CMC-Na
				Tyloxapol
20	Paclitaxel	Anticancer	Emulsification+high speed homogenization	Poloxamer-188	0.5%	Solubility enhancement	111
21	Quercetin	Antioxidant	HPS	Tween-80	2%	Solubility enhancement	37
			Bead milling
			Cave precipitation
22	Baicalein	Anticancer	Antisolvent recrystalization + high pressure homogenization	Polysorbate -80	0.1%–0.5%	Solubility enhancement	20
				SLS
				Poloxamer-188
23	Puerarin	Cardiovascular system	High pressure homogenization	Sodium dodecyl sulphate	3.75%	Solubility enhancement	112
24	Docetaxel	Anticancer	High shear homogenization	Pluronic F-127	1%–5%	Targeted delivery	113
				Pluronic F-68
				Tween-80
25	Curcumin	Anticancer	Media milling	Tween-80	0.2%	Solubility enhancement	114
26	Benzimidazole	Anticancer	Nanoprecipitation, media milling	Pluronic F-108	10%	Bioavailability enhancement	115
				Tween-80
27	Itraconazole	Antimycotic agent	Pearl milling technique	Poloxamer-407	3%	Solubility enhancement	51
28	Nimodipine	Calcium-channel blocker	High pressure homogenization	Poloxamer-188	0.6%	Solubility and bioavailability enhancement	116
				Tween-80	0.5%
29	Asulacrine	Anticancer	High pressure homogenization	Poloxamer	1%	Bioavailability enhancement	117
30	Nevirapine	Antiretroviral	High pressure homogenization	Tween-80	1.0%	Targeted delivery	118
				Poloxamer-188	0.5%0.3%
				PVP
31	Oridonin	Anticancer	High pressure homogenization	Pluronic f-68	0.5%	PK and tissue distribution study	119
				Lecithin
32	1,3-Dicyclohexylurea	Antihypertensive	Wet media milling	PVP	20%	PK evaluation	120
33	Ibuprofen	Anti-inflammatory	Nano-precipitation	Tween-80	0.02%	Bioavailability enhancement	121
34	Acyclovir	Antiviral	Nano-precipitation	Tween-80	0.02%	Bioavailability enhancement	122
35	Hydrocortisone, prednisolone	Glucocorticoid	High-pressure homogenization	Pluronic F-68	0.1%	Targeted and delayed drug delivery	123
36	Fluticasone	Anti-inflammatory	Wet media milling technique	Tween-80	0.5%	Targeted drug delivery	124
37	Sulfacetamide	Antibiotic	Nano-precipitation	Pluronic F-68	1%	Targeted drug delivery	125
38	Cloricromene	Antithrombotic and antiplatelet	Nano-precipitation	Tween-80	0.02%	Bioavailability and stability enhancement	126
39	Camptothecin	Antitumor	Anti-solvent precipitation with sonication	Pluronic F-127	Not reported	Targeted delivery	127
				PVP-K30
				HPMC
				PEG 8000
40	Paclitaxel	Antitumor	Wet media milling	Pluronic F-127	1%	Targeted delivery	128
41	Budesonide	Glucocorticoid	High pressure homogenization	Span 85	0.5%	Targeted delivery	129
				Lecithin	0.5%
42	Deacety mycoepoxydiene	Anticancer	High pressure homogenization	Poloxamer 188	0.5%	Solubility enhancement	130
				Lecithin	0.5%
				HPMC	0.1%
				PVP	0.1%
43	Atovaquone	Antimicrobial	High pressure homogenization	Tween 80	0.1%	Targeted delivery	131
				Poloxamer 184	0.1%
44	Bupravaquonone	Antibiotic	High pressure homogenization	Poloxamer 188	1.0%	Targeted delivery	132
				Lecithin	0.5%
45	Omeprazol	Proton pump inhibitor	High pressure homogenization	Poloxamer 188	1%	Stability enhancement	133

׳–׳ Data not available.